Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kin Meds vs Trillium Meds

Kin Meds
Graded #75

Higher grade

vs+3.5
Trillium Meds
Graded #130

Lower grade

The verdict

Kin Meds takes it — 72.9/100 to 69.4/100.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +4
74
70
Dose & formulationKin Meds +29
93
64
Clinical oversightTrillium Meds +10
74
84
Labs & monitoringTrillium Meds +22
53
75
FulfillmentTrillium Meds +7
72
79
Contract termsKin Meds +35
55
20
Kin Meds · left barTrillium Meds · right bar

The numbers

MetricKin MedsTrillium Meds
WeighScore72.9/10069.4/100
GradeCC
Scorecard rank#75#130
Semaglutide$149/mo (brand Wegovy)$119/mo (3-month plan, compounded)
Tirzepatide$149/mo (brand Zepbound)$199/mo (3-month plan, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Kin Meds

Graded #75 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described
Trillium Meds

Graded #130 · C

Strengths

  • LegitScript certified with an active seal; serves all 50 states plus Puerto Rico with no geographic restrictions
  • All-inclusive pricing covers medication, provider consultation, and shipping with no hidden fees or add-ons
  • Two pharmacy options (BPI Labs with B6, ProRx) and three plan structures: 1-month, 3-month fixed, or 3-month titrated
  • Small owner-operated; founder personally handles customer support outside business hours for direct, responsive service
  • Klarna and Affirm financing available; pause anytime with no long-term commitment required

Where it loses points

  • No labs, coaching, or clinical monitoring included — telehealth Rx and pharmacy fulfillment only
  • Small single-operator platform may limit capacity and support consistency as patient volume grows
  • Compounded medications are not FDA-approved; newer platform with limited long-term public track record
  • Tirzepatide from $199/mo (3-mo plan) is mid-market; sema from $119/mo competitive but not lowest available
  • No live video consult disclosed; async intake-form-based provider review by external licensed provider network

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard